Mazdutide

Name: Mazdutide
Brand: LyoPep

GLP-1 / glucagon dual agonist · metabolic research peptide (IBI362 / LY3305677)

≥ 99.0% · target, verify batch COACAS 2259884-03-0RUO

MOQ1 kit (10 vials) per SKU

Supplied formTritriacontapeptide (linear, 33-residue oxyntomodulin/GLP-1-glucagon dual-agonist analog, lipidated — C20 fatty-diacid conjugation at Lys20 via gammaGlu-AEEA-AEEA linker)

Lead time14–21 days

Mazdutide — Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA

Mazdutide — Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes GLP-1R/GCGR dual-receptor pharmacology, structure-activity and energy-expenditure models, lipidated-peptide analytical methods, formulation and albumin-binding studies, and comparison with other incretin multi-agonist standards
These are not weight-loss, glycemic or liver-fat benefit claims for this product.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 2259884-03-0
Formula: C₂₁₀H₃₂₂N₄₆O₆₇
Molecular weight: 4563.07 g/mol
Appearance: Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture and light as specified. Qualify solvent, pH, concentration, container, temperature and hold time after reconstitution; do not infer a universal frozen shelf life.
MOQ: 1 kit (10 vials) per SKU
Lead time: 14–21 days

PubChem CID 167312357

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Mazdutide

Mazdutide is an oxyntomodulin-related synthetic peptide designed to activate GLP-1 and glucagon receptors and bearing a long-chain fatty-diacid albumin-binding modification. Its exact published structure representation is not fully consistent across public databases, making lot-level sequence, linker and mass documentation essential.

GLP-1R/GCGR dual signaling; receptor pharmacology and structure-activity work; lipidated-peptide identity and impurity methods; albumin-binding, formulation and stability research; controlled comparison with survodutide, tirzepatide or retatrutide reference standards.

Mechanism context

The question the literature is testing

Mazdutide activates GLP-1R and GCGR in assay- and species-dependent systems. GLP-1R/GCGR dual agonism is studied as a combination of appetite, glycemic and energy-expenditure pathways, while lipidation supports albumin association in drug development. Vendor Ki values are not treated as universal potency constants.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaMetabolic and incretin research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Research Use Only; not a sterile finished drug and not for human or veterinary use
Adverse events and contraindications from clinical studies or a jurisdiction-specific label describe the tested finished formulation, not this lot
Handle under the SDS and institutional risk assessment.

Interactions reported in the literature

For bench studies, control receptor expression, glucose, albumin or serum content, assay timing and comparator concentration
No clinical combination with insulin, semaglutide, metformin, GH-axis peptides or other products is recommended.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Mazdutide batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

5 mg
10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Require exact sequence, termini, non-natural residues, lipidation site and linker identity, RP-HPLC purity with method, intact mass, LC-MS/MS modification evidence, peptide content, related substances, counterion, water and residual solvents
Appearance or clear reconstitution cannot establish identity, endotoxin, sterility or suitability.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

MAZ55 mg10 vials

MAZ1010 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap — 10 mL nasal spray bottle

Besides lyophilized vials, Mazdutide is also supplied as a nasal spray solution, shipped from our US stock.

Strengths: 10 mg
Bottle sizes: 10 mL or 20 mL
Minimum order: 10 bottles per strength and bottle size
Ships from: Our US stock

Handling

Plan storage before the parcel arrives

Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture and light as specified. Qualify solvent, pH, concentration, container, temperature and hold time after reconstitution; do not infer a universal frozen shelf life.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity and nomenclature: PubChem CID 167312357 and IUPHAR/BPS ligand 13924. Formula discrepancy cross-check: KEGG D12225 and FDA GSRS. Clinical evidence context: GLORY and DREAMS primary reports. China approval chronology is supported by Innovent’s June and September 2025 notices; sponsor claims are not transferred to this RUO lot. A March 2026 FDA warning letter expressly treated mazdutide products marketed by the cited US vendor as unapproved new drugs, supporting the US boundary without implying that the warning letter evaluates this lot.

01
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
New England Journal of Medicine · 2025 · peer-reviewed original research (phase 3 randomized controlled trial, GLORY-1)
Open source
02
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Nature · 2026 · peer-reviewed original research (phase 3 randomized controlled trial, DREAMS-1)
Open source
03
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Nature · 2026 · peer-reviewed original research (phase 3 active-comparator randomized controlled trial, DREAMS-2)
Open source
04
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Nature Communications · 2023 · peer-reviewed original research (phase 2 randomized controlled trial)
Open source
05
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
eClinicalMedicine (The Lancet Discovery Science) · 2022 · peer-reviewed original research (phase 1b randomized controlled trial)
Open source
06
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials
Diabetes, Obesity and Metabolism · 2026 · peer-reviewed systematic review / meta-analysis
Open source
07
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Diabetes (American Diabetes Association) · 2009 · peer-reviewed original research (foundational preclinical study)
Open source
08
What is the pipeline for future medications for obesity?
International Journal of Obesity · 2025 · peer-reviewed narrative review (independent expert commentary including mazdutide)
Open source

Product FAQ

Questions buyers ask about Mazdutide

Where does Mazdutide sit in the incretin receptor-coverage series?+

Receptor coverage distinguishes the named molecules: tirzepatide targets GIPR + GLP-1R, mazdutide targets GLP-1R + GCGR, and retatrutide targets GIPR + GLP-1R + GCGR. This is a classification, not proof of matched potency, signaling bias, exposure or efficacy. A comparison must verify each lot's exact identity and use matched receptor expression, molar concentration, albumin or serum conditions and assay timing.

Why must Mazdutide identity be verified per COA?+

CAS 2259884-03-0 is linked to mazdutide by PubChem and IUPHAR/BPS, but public formula and structure records conflict. The COA should therefore state the full modified sequence, lipidation site and linker, counterion, theoretical mass and observed intact mass. A regulatory approval for a named finished formulation does not resolve the identity of a separate research lot.

Should a lab source Mazdutide or Survodutide for GLP-1 / glucagon dual-agonist work?+

Both are designed for GLP-1R + GCGR agonism without a GIPR arm, but they have different sequences, lipidation chemistry and receptor-pharmacology profiles. The choice is therefore both mechanistic and documentary: align the reference material to the molecule and evidence set being studied, qualify exact identity per batch COA and do not treat them as interchangeable controls.

Evidence before order

Buyer intelligence

Ready for review

Request a usable quote

Include fill, quantity, target purity/content, required methods, destination and timing.

B2B response target: 24 hours
1 kit MOQ per SKU
Batch COA: HPLC, MS, endotoxin, fill

Research Use Only. Human-use requests are not accepted.

Recent activity window

Recent confirmed orders including Mazdutide

Recent Confirmed Orders7 · Last 30 days

United States19 g2026-11-13

GLOW (BPC+GHK-Cu+TB) 70 mg · Mazdutide 10 mg · TB-500 10 mg · CJC-1295 + Ipamorelin 10 mg · PE-22-28 10 mg · Retatrutide 60 mg · GHRP-6 10 mg · KPV 10 mg · Bacteriostatic Water 10 ml

Thailand500 mg2026-11-13

Semaglutide 30 mg · Survodutide 10 mg · SS-31 5 mg · Mazdutide 5 mg · Bacteriostatic Water 3 ml

United States150 mg2026-11-10

Retatrutide 5 mg · Mazdutide 5 mg

United States1.1 g2026-11-07

NAD+ 100 mg · Mazdutide 5 mg · PT-141 10 mg · Bacteriostatic Water 10 ml

Belgium600 mg2026-10-30

TB-500 10 mg · Mazdutide 5 mg · BPC-157 5 mg · Bacteriostatic Water 10 ml

United States14.6 g2026-10-29

Tirzepatide 120 mg · IGF-1 LR3 1000 mcg · Mazdutide 10 mg · BPC-157 10 mg · LL-37 5 mg

Canada1.6 g2026-10-19

Dulaglutide 10 mg · PE-22-28 10 mg · BPC-157 10 mg · Mazdutide 5 mg · Bacteriostatic Water 3 ml

Only a portion of all confirmed orders is shown here.

Mazdutide

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Mazdutide

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Mazdutide batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Also available as a nasal spray (US stock)

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

Mazdutide versus placebo in Chinese adults with type 2 diabetes

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

What is the pipeline for future medications for obesity?

Questions buyers ask about Mazdutide

Buyer intelligence

Compare adjacent molecules and documentation needs.

Survodutide

Retatrutide

Tirzepatide

Semaglutide